GleamWall
中文EN

CLLS Cellectis S.A. IFRS

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1627281 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY75.8%
TTM net income YoY-83.9%
TTM EPS YoY-63.4%
Revenue 3-yr CAGR56.1%
Net income 3-yr CAGR—

Margins

Gross margin100.0%
Operating margin-45.3%
Net margin-92.7%
FCF margin-57.2%
EBITDA margin-17.8%

Returns

ROE-65.3%
ROA-19.1%
ROIC (approx.)-2,430.7%
Asset turnover0.21x

Leverage & solvency

Liabilities / assets76.6%
Debt / equity0.00x
Current ratio—
Interest coverage-0.65x

Cash quality & payout

Operating cash flow / net income0.58x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue3.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31 · USDFY20242024-12-31 · USD
Income statement
Revenue$72.95M$41.51M
Cost of revenue$0$0
Gross profit$72.95M$41.51M
R&D expense$93.52M$90.54M
SG&A expense$19.79M$19.09M
Operating income-$33.08M-$59.55M
Interest expense$51.06M$21.61M
Pretax income-$68.02M-$36.76M
Income tax-$423,000$0
Net income-$67.59M-$36.76M
EBITDA-$13.01M-$39.71M
EPS (basic)-0.67-0.41
EPS (diluted)-0.67-0.41
Weighted avg. shares (diluted)100.28M90.57M
Balance sheet
Cash & equivalents$61.53M$143.25M
Short-term investments$144.80M$115.80M
Receivables$14.40M$6.71M
PP&E, netmay include right-of-use assets (IFRS)$38.79M$45.90M
Intangibles$535,000$1.12M
Total assets$324.72M$383.54M
Current liabilities$145.75M$166.27M
Total liabilities$248.82M$252.51M
Shareholders' equity$75.90M$131.03M
Shares outstanding100.34M100.09M
Cash flow statement
Operating cash flow-$39.40M$22.99M
Capital expenditure$2.36M$2.58M
Free cash flow-$41.76M$20.41M
Investing cash flow-$29.48M-$102.81M
Financing cash flow-$16.76M$89.11M
Depreciation & amortization$20.06M$19.85M
Stock-based compensation$6.11M$3.17M

Free plan shows the latest 2 periods; Pro shows all 12 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.